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Abstract :  
 
Background Context: Walking limitations caused by neurogenic claudication (NC) are 
typically assessed with self-reported measures, though objective evaluation of walking 
utilizing motorized treadmill test (MTT) or self-paced walking tests (SPWT) have 
periodically appeared in the lumbar spinal stenosis (LSS) literature. 
 
Purpose: This study compared the validity and responsiveness of MTT and SPWT for 
assessing walking ability before and after common treatments for NC. 
 
Study Design: Prospective, observational cohort study  
 
Patient Sample: 50 adults were recruited from an urban spine center if they had LSS, 
substantial walking limitations from NC, and were scheduled to undergo surgery (20%) 
or conservative treatment (80%).   
 
Outcome Measures: Walking times, distances and speeds along with characteristics of 
NC symptoms were recorded for MTT and SPWT. Self-reported measures included back 
and leg pain intensity assessed with 0 – 10 numeric pain scale, disability assessed with 
Oswestry Disability Index (ODI), walking ability assessed with estimated walking times 
and distances, and subscales from the Spinal Stenosis Questionnaires (SSQ). 
 
Methods: MTT used a level track, and SPWT were conducted in a rectangular hallway. 
Walking speeds were self-selected and test endpoints were: a) NC, b) fatigue, or c) 
completed the 30-minute test protocol. Results from MTT and SPWT were compared 
with each other and with self-reported measures. Internal responsiveness was assessed by 
comparing changes in initial to post-treatments results, and external responsiveness by 
comparing walking test results between those that improved with those that did not 
improve by self-report criteria. 
 
Results: Mean age was 68 years. 58% were male. NC included leg pain (88%), and 
buttock(s) pain (12%). 5 participants could not safely perform MTT. Walking speeds 
were faster and distances were greater with SPWT, although results from both tests 
correlated with each other and with self-reported measures. 72% of participants reported 
improvement following treatment which was confirmed by significant mean differences 
in self-reported measures. MTT results did not demonstrate internal responsiveness to 
change in clinical status following treatment, but SPWT did with increased mean walking 
times (6 min) and distances (387 m). When responsiveness was assessed against external 
criterion, both SPWT and MTT demonstrated substantial divergence with self-reported 
changes in clinical status and alternative outcome measures.  
 
Conclusions: Both MTT and SPWT can quantify walking abilities in NC. As outcome 
tools, SPWT demonstrated better internal responsive than MTT, but neither test 
demonstrated external responsiveness. Neither test should be considered as a meaningful 
substitution for disease specific measures of function. 
 INTRODUCTION 
With advancing age, spinal degeneration can cause substantial structural changes in the 
lumbar spine. In some adults these changes result in progressive narrowing of the spinal 
canal and compression of the lumbar nerve roots - a condition referred to as lumbar 
spinal stenosis (LSS) [1-3]. In population-based studies, moderate LSS is noted in up to 
40 percent of adults over the age of 60, though most do not report symptoms [4].  
 
For symptomatic adults with imaging studies demonstrating LSS, neurogenic 
claudication (NC) is the symptom complex that most spine experts agree is attributable to 
LSS [5]. NC is defined as intermittent pain radiating to the buttock(s), thigh(s) and/or 
lower leg(s) that is induced with standing, walking and/or lumbar extension, and relieved 
with sitting, lying down or lumbar flexion [5]. When of severe intensity, NC causes 
considerable limitations for walking [6,7]. These limitations drive many elderly adults to 
seek medical care, and are the most frequent reasons for lumbar spine surgery in 
Medicare recipients [8]. 
 
Because limited walking is the most relevant area of impaired function for patients with 
NC, improvement of walking abilities is the primary goal of most treatments [5]. For this 
reason, assessment of patients’ ability to walk is a standard part of the evaluation of NC.  
Typically, in both clinical practice and research, walking limitations are assessed through 
direct questioning (example:  “How far or long can you walk on even ground without a 
break?) [9,10], or through disease-specific disability questionnaires [11-13]. Although 
self-reported measures of walking are certainly meaningful, actual quantification of 
walking ability would seem to be a useful endeavor for assessment of NC, and may aid in 
the objective evaluation of the effects of treatments.  To date, motorized treadmill tests 
(MTT) are the most frequently cited methods for quantifying walking ability of patients 
with NC [10,14-24]. 
 
Recently, several observational studies have reported on self-paced walking tests (SPWT) 
that directly observe walking time and distance as patients with NC walk on level 
walking courses [25-29]. SPWT has obvious validity, as it directly observes the function 
of interest under conditions representative of real world settings, such as walking in a 
shopping mall, and therefore meets the first requirement of an outcome measure for 
clinical trials [25, 26]. Because of its validity, SPWT results have been used as a criterion 
standard to assess the accuracy of other measures for quantifying walking limitation 
caused by NC, including MTT [29], and self-reported measures [30]. SPWT also has 
adequate test-retest reproducibility [29], and thus meet the second requirement of an 
outcome measure for use in clinical trials.  
 
The third requirement of an outcome measure is responsiveness, and this has not been 
explored for SPWT. Responsiveness has two major aspects [31]. The first aspect is 
internal responsiveness, which assesses the ability of a measure to change over a pre-
specified time frame, such as before and after an intervention. Since internal 
responsiveness evaluates the ability of a measure to detect change, it is dependent on the 
effectiveness of the intervention utilized to induce change. Of importance, internal 
responsiveness is assessed independent of changes in other outcome measures, and 
therefore it does not necessarily speak to the relevancy of the detected changes compared 
to overall changes in clinical status. The second aspect of responsiveness, external 
responsiveness, reflects the relevance of changes detected by a measure by evaluating its 
relationship to corresponding changes in a reference standard of clinical status. External 
responsiveness is dependent solely on the choice of the reference standard, and not on the 
treatment under investigation. External responsiveness allows the assessment of whether 
a change in the measure can be viewed as an accepted indicator of a meaningful change 
in the condition of a patient, and the appropriateness of using the measure as a substitute 
for alternative reference standards [31]. 
 
The purpose of this study was to explore the utility of SPWT and MTT for evaluating 
walking limitations produced by NC in a group of patients undergoing common 
treatments for this condition. Specific factors under study included comparison of each 
tests ability to quantify walking limitation produced by NC and evaluation of internal and 
external responsiveness. 
 
MATERIALS AND METHODS 
Participants 
This study received Investigational Review Board approval and all participants signed an 
informed consent.  
 
Participants were recruited from a spine center of an urban, academic hospital by 4 
physiatrists with extensive experience in treating spinal disorders. Inclusion criteria were: 
1) degenerative lumbar spinal stenosis documented by lumbar MRI or CT scan; 2) 
walking induced NC with or without concurrent neurological symptoms of weakness, 
sensory loss or impaired balance [5]; 3) self-reported walking ability limited by NC to 30 
minutes or less; 4) duration of NC of at least 3 months; and 5) scheduled to undergo 
physical therapy, spinal injections or surgery as treatment for NC. Exclusion criteria 
were: 1) symptoms of buttocks and leg pain not aggravated by walking; 2) concurrent 
acute disc herniation as the probable cause of symptoms; 3) spinal stenosis caused by 
non-degenerative spinal disorders (neoplasm, metabolic bone disease, vertebral fracture); 
4) non-palpable dorsalis pedis and posterior tibial pulses in the symptomatic leg(s) 
suggesting possible peripheral vascular insufficiency; 5) symptomatic arthritis of the hip, 
knee, ankle or foot causing limitation in walking; 6) neurological disease affecting 
ambulation (Parkinson’s disease, myelopathy, stroke); 7) cardiac or pulmonary disease 
that limits walking; 8) severe cognitive difficulties; 9) general frailty that would make 
participating in the walking test unsafe.  
 
Assessments 
The enrolling physiatrists complete a study questionnaire that recorded demographics, 
duration, location and intensity of symptoms, physical examination findings, burden of 
co-morbidities (range 0-42 with higher scores for increasing burdens of co-morbidities) 
[32], and the level(s) of spinal stenosis. Spinal stenosis of the central canal was defined as 
reduction of the CSF signal in MRI T2 axial and sagittal images, and the degree of 
stenosis defined as Grade 1 for 1/3 reduction of canal area, Grade 2 for 1/3 to 2/3 
reduction of canal area, and Grade 3 for greater than 2/3 reduction of canal area [33]. 
 
 
All participants completed the following paper and pencil measures. NC induced 
limitations in walking were assessed by questions that asked participants to estimate the 
1) distance (in feet, yards or miles) and 2) time (in minutes or hours) that they could walk 
without a break on even ground in a typical community setting before symptoms become 
intolerable [10]. Participants were also asked to estimate the intensity of NC back and leg 
pain induced by walking in community settings over the last week utilizing an 11-point 
numerical pain scale anchored with 0 (no pain) and 10 (worst possible pain) [34]. NC 
symptoms were also assessed using the validated Spinal Stenosis Questionnaire (SSQ) 
Symptom Severity and Physical Function Subscales [12,13,35,36]. These subscales are 
scored between 1 and 5 with higher values indicate greater symptoms and physical 
limitations. Finally, total scores from Oswestry Disability Index Version 2.0 (ODI) (range 
0-100% disabled), and scores from the ODI item assessing walking ability (range 0-no 
limitations to 5- can walk only a few steps) were recorded [11]. 
 
Changes in clinical status were assessed using two methods. Global change in clinical 
status was assessed with the following question. “Since treatment, how have your 
symptoms with walking changed?  (Choose 1) Completely resolved; Improved but are 
still present; No changed; Worsened” Additionally, at the time of final testing, 
participants completed the numeric pain scales, self-reported walking distance and 
walking time questions, SSQ symptom severity, SSQ physical function and ODI. These 
results were contrasted with initial results and changes in scores were calculated. 
Participants also completed the SSQ satisfaction subscale with range of scores from1 – 
most satisfied to 4 – very dissatisfied.  
 
Walking tests 
Walking tests were performed at a hospital-affiliated physical therapy facility located in a 
medical office building. Testing sessions were scheduled within one week of study entry, 
and before any treatments for NC were administered. SPWT and MTT were administered 
by the same research physical therapist on the same day separated by at least a 5 minute 
rest or until all symptoms from the first test had resolved. The sequence of walking tests 
during all test sessions was determined by a random number table that pre-assigned the 
first test (SPWT or MTT) based on the order of subject enrollment. 
 
The SPWT was conducted on a 52 meter (170 feet) rectangular course in the carpeted 
corridors of the medical building in which the physical therapy site was located. Chairs 
were positioned at three locations along the walking course so that participants would 
always be within 10 meters of a seat in case they felt unable to stand or walk. Study 
participants sat in a chair at the starting line, and the test began when they stood and 
began walking around the course at a self-selected pace. The research physical therapist 
walked approximately one meter behind the participants during the entire test, and 
recorded the walking time with a stopwatch and laps with a hand held mechanical 
counter. Distances of partial laps were estimated from pre-placed marks every 10 meters 
along the course. 
 
MTT was conducted with the incline of the treadmill set at zero degrees. In order to 
prevent participants from potentially improving their walking by bending forward [14], 
participants were not allowed to place both hands on the handrails for support, but were 
allowed to use one hand on the handrail for balance, if needed. Walking speed was 
determined during a pre-test walk on the treadmill during which the speed was adjusted 
until the subject reported that they were walking at their desired speed. After the brief 
pre-test, participants sat for at least two minutes before the actual test began. The time of 
walking was measured with a stopwatch. For repeat testing, the original walking speed 
was selected at beginning of the pre-test walk on the treadmill and adjusted per request of 
participants during the test, until the desired walking speed was found. 
 
For both SPWT and MTT, the ability of the walking test to produce NC was recorded as 
a “positive” result. The test was terminated when their symptoms reached the intensity at 
which participants would usually stop walking in a community setting.  The tests were 
stopped immediately by the participants for reasons of fatigue, and the results were 
recorded as “negative - fatigue”. For participants that completed the 30 minute protocol 
without developing symptoms, results were recorded as “negative – completed without 
symptoms”. Results for each test were recorded for walking time in minutes (min.), speed 
in kilometers per hour (km/h), and distance in meters (m). Following completion of each 
walking test, participants completed a questionnaire inquiring about the characteristics of 
NC symptoms (pain location, pain intensity, presence of neurological symptoms).  
 
Interventions 
This study utilized typical treatments for neurogenic claudication as the interventions to 
produce change of status against which both internal and external responsiveness could 
be assessed. Because our goal was to assess responsiveness of SPWT and MTT, and not 
treatment, we included participants undergoing non-surgical (exercise-oriented physical 
therapy, lumbar spine injections with corticosteroids, or both) and surgical treatments 
(decompression with or without fusion) for neurogenic claudication.  It was assumed that 
this would lead to a wide range of changes in clinical status, which when measured, 
would be adequate for assessing responsiveness of SPWT and MTT. Assessment of the 
effectiveness of any particular treatments was not an objective of this study, and therefore 
not performed. For participants undergoing physical therapy, post-treatment testing was 
done at discharge from therapy (average therapy time of 6 weeks).). For participants 
undergoing spinal injections only, reassessment was done at 4 weeks after injections. For 
participants undergoing spine surgery, reassessment was done 3 months after surgery. 
 
 Statistical Methods 
 
Data analysis was performed with SPSS 14.0 (SPSS, Chicago, IL). 
 
To explore their ability to assess NC, results of initial walking times, distances, and 
walking speeds were compared between SPWT and MTT using paired-sample t-tests and 
intraclass correlation coefficients (ICC). ICC was chosen for this analysis as it assesses 
the conformity of observations by two different measures of the same variable expressed 
in the same units [37]. The κ (kappa) coefficient was used to measure the agreement in 
the ability of the two walking tests to reproduce NC symptoms [38].  Pearson product 
moment correlations were used to compare results from SPWT and MTT with self-
reported walking measures. 
 
This study utilized two statistical methods to evaluate internal responsiveness [34]. First, 
paired sample t-test were calculated to assess change between initial and final SPWT and 
MTT scores. Next, standardized effect size (ES) were used to assess the magnitude of 
changes in SPWT and MTT compared to the variance (standard deviation) in those 
measures at baseline assessment [39].  The values for ES are commonly interpreted as 
.20, .50 and .80 or greater as indication small, moderate or large internal responsiveness, 
respectively.  
 
External responsiveness was assessed using 2 statistical methods. Receiver operating 
characteristics curves (ROC) were plotted and area under the curve (AUC) were 
calculated to explore the degree to which specific values of change scores for SPWT and 
MTT walking times and distances correctly reflect the reference standard of improved or 
not improved clinical status [40]. This reference standard was derived from lumping 
responses to the change in clinical status question into 2 categories - improved (combined 
‘completely resolved’; ‘improved but are still present’) and not improved (combined 
‘unchanged’ and ‘worsened’). The validity of this reference standard was first confirmed 
by comparing the change scores of low back pain, leg pain, ODI, SSQ symptom, and 
SSQ function, and raw scores of SSQ satisfaction between participants classified as 
improved and not improved using independent sample t-test. The external responsiveness 
of the walking test related to alternative outcomes was examined by comparing change 
scores of SPWT and MTT with change scores for self-report walking, SSQ physical 
function and ODI walking score using Pearson product moment correlations.  
 
RESULTS 
Fifty participants participated in this study. Their average age was 68 years old (standard 
deviation [SD] 7.9, range 48-86) and the average duration of NC was 18 months (SD 21). 
The majority of participants were white (92%), male (58%), retired (54%), and highly 
educated (16.7 years, SD 3.4). Mean co-morbidity score was 5.1 (SD 4.5). Lumbar spine 
imaging was by MRI in 94% of participants and the remainder had CT. L3-4 and L4-5 
were the most common levels of spinal stenosis (56% and 82 % respectively) with ≥2 
stenotic levels noted in 42% of participants. Stenosis was rated as severe in 54% and 
moderate in 38% of participants. Neurogenic claudication symptoms included leg pain in 
88% of participants (bilateral in 54%), with buttocks pain in the remaining 12%. Walking 
induced low back pain was reported by 82%. Mean self-reported intensity of NC leg pain 
was 5.7 (SD 2.6) and back pain was 6.0 (SD 2.5). Eighty-two percent of participants 
reported that walking produced one or more neurological symptoms. These included 
paresthesias (58%), leg weakness (38%) and unsteadiness (38%). 
 
Initial Walking Test Results 
Twenty seven participants were randomly assigned to first undergo MTT, and the 
remaining 23 to first undergo SPWT.  Five participants could not walk safely on the 
treadmill without both hands on the handrail, and therefore did not undergo MTT. These 
5 participants were older, more disabled, and had higher comorbidity scores than the 
participants that could safely walk on a treadmill. Of the 45 participants undergoing 
MTT, 12 were able to walk the full 30 minutes, with 5 completing the test without 
symptoms. All 50 participants underwent SPWT, with 12 walking the full 30 minutes, 
and 2 completing the test without symptoms. 
 
For the 45 participants that completed both walking tests, results demonstrated that both 
SPWT and MTT have similar abilities for quantifying walking and reproducing 
symptoms in patients with NC (Table 1). Walking times were similar for both tests and 
showed a high correlation (ICC .79, P≤.001). Walking speeds were faster and walking 
distances greater during SPWT, though results showed high correlations between the two 
tests (walking speed ICC .50, P≤.001, walking distance ICC .84, P≤.001). Both test had 
similar abilities to reproduced NC symptoms with modest agreement between test for 
walking induced back pain (κ = .43, P ≤.01), leg pain (κ = .45, P ≤.01), paresthesias (κ = 
.77, P ≤.001), leg weakness (κ = .69, P ≤.001), and unsteadiness (κ = .79, P ≤.001). Self-
reported estimated walking times (mean 16.5 minutes) and distances (mean 778 meters) 
were statistically similar (t-test P not significant) to actual results from MTT and SPWT. 
Results form both test demonstrated similar correlations with self-reported walking 
measures (Table 2).  
 
Responsiveness 
Eleven of the 50 participants did not return for retesting, with 6 not willing to return, 3 
not showing for 2 scheduled retesting sessions, and 2 developing unrelated medical 
problems that disqualified them from undergoing final walking tests. Six of these 11 
participants had undergone spine surgery. Of the 39 participants that were reassessed 
after treatment(s), 33% received physical therapy alone, 26% had spinal injections only, 
31% had both physical therapy and spinal injection, and 10% underwent spine surgery. 
Only 32 participants underwent the final MTT, as 5 participants remained unable to 
undergo testing for safety reasons and 2 participants refused to undergo MTT during the 
final test session. All 39 participants underwent the final SPWT. 
 
Comparisons of initial and post-treatment results from self-reported measures suggested 
that modest change in pain and function had occurred (Table 3), making assessment of 
responsiveness plausible. Change in global clinical status was also observed, as 28 
participants reported that they had improved (6 symptoms resolved and 22 improved), 
and 11 participants reported they had not improved (9 unchanged and 2 worsened). 
Validation of this grouping was confirmed by comparing change scores for self-reported 
measures using independent sample t-test , and significant greater improvements in 
scores were noted between the improved and not improved groups for self-reported 
walking time, back pain, leg pain, ODI walking and SSQ physical function (all P ≤ .01). 
Differences between improved and not improved groups approached but did not reach 
statistical significance for self-reported walking distance, ODI total scores and SSQ 
symptom scores. SSQ satisfaction scores were more favorable for the improved than the 
not improved participants (P < .01). 
 
Table 4 presents internal responsiveness results. MTT walking time and distance did not 
significantly change which suggests that internal responsiveness was negligible under the 
treatment conditions of this study. In contrast, SPWT demonstrated modest internal 
responsiveness, as walking time and distance did significantly change following 
treatment. When SPWT results were analyzed for just the 32 participants that also 
completed MTT, the results were similar (data not presented). Walking speed lacked 
internal responsiveness for both test.  
 
 Evaluation of external responsiveness revealed that neither SPWT nor MTT 
demonstrated meaningful capabilities. Figure 1 presents ROC for SPWT and clearly 
demonstrates that changes in SPWT walking time (AUC = .545) or distance (AUC = 
.564) did not differentiate between improved and not improved participants. Figure 2 
presents ROC for MTT, which performed slightly better than SPWT for walking time 
(AUC =.717) and distance (AUC =.702), though these results did not reach statistical 
significance.  
 
Correlations between changes in MTT and SPWT walking times and distances with 
changes in self-reported measures are reported in Table 5. Changes in MTT results 
correlated with change in self-report walking time and distance, whereas SPWT did not. 
When compared to changes for other self-reported measures of walking, MTT walking 
time correlated with changes in ODI walking item. Changes in SPWT and MTT walking 
distance showed significant correlations only with SSQ physical function. 
 
DISCUSSION 
Validation of Walking Tests 
This study supports the findings of others that limitations of walking caused by NC can 
be quantified using MTT [10,14-24] and SPWT [25-29]. Results from both MTT and 
SPWT showed strong correlations with each other and with self-reported walking 
abilities, offering further validation that both walking test assess limitation that are 
characteristic of NC to a similar degree [24,30]. 
 
Both MTT and SPWT produced comparable results in terms of walking times, 
confirming the observation of Tomkins et al [29]. Walking speeds were slower for MTT 
than SPWT, and therefore the walking distance covered during similar walking times 
until onset of significant symptoms were shorter for MTT, a result also noted by Tomkins 
et al [29].  Of interest, similar observations by these two studies suggest that the duration 
of walking may be the most limited factor for production of NC, and slower pace of 
walking (as noted during treadmill walking) may afford little benefit in terms of total 
distance walked.  
 
The reason for slower walking during MTT might related to caution while on this 
equipment that resulted from participants’ unfamiliarity or unease with treadmill walking. 
If this is correct, MTT might systematically underestimate walking distances in NC 
similar to what was noted in studies of pulmonary diseases [41]. One must also consider 
that the shared walking experience between the test subject and the examiner during 
SPWT may have inadvertently resulted in pacing of the subject by the examiner. If true, 
pacing might have been an unanticipated, but important source of bias that may have 
elevated participants’ walking speed and distances above the levels that would have 
occurred with unaccompanied walking. 
 It is of some concern that our MTT protocol, which disallowed holding the handrail with 
both hand, disqualified 10% of our participants from performing this test. Moon et al also 
reported that some participants with LSS cannot safely walk on a treadmill [21]. As these 
participants were older and generally more impaired, MTT may be less plausible as an 
outcome measure in clinical trials that focus on more frail individuals with NC. In 
contract, SPWT which mimicked real world walking situations could be performed by all 
study participants. 
 
Even with the 30 minute protocols for SPWT and MMT and selection of participants with 
self-reported walking ability of 30 minutes or less, we found significant ceiling effect in 
this study. As one might expect, the influence of ceiling effect increased during the study 
with nearly one half of our participants completing the SPWT and one third completing 
MTT without symptoms at final testing. Though this improvement offers objective 
evidence of improved walking abilities, the completion of walking test protocols before 
symptoms were induced caps the measured walking times and distances below their true 
levels. This under measurement of walking abilities produced an underestimation of 
treatment response by these measures. This may be particularly problematic when using 
walking tests to assess outcomes in those with only modest limitations in initial walking 
(and therefore more likely to undergo conservative care), along with those who have the 
most dramatic improvements in walking abilities in response to treatment. This influence 
of ceiling effect on measurement of walking ability would obviously be far greater when 
walking test time utilize protocols of less than 30 minutes [10]. 
 
A clear disadvantage of SPWT is its requirement for an appropriate space for the walking 
course. We were fortunate to have access to a rectangular public corridor in a medical 
office building that was similar to the walking courses used by others [27,28]. The 
availability of an appropriate space for a walking course may be a significant barrier to 
the adoption of SPWT as a widely used outcome measure for clinical trials, especially 
when compared to the space requirements for MTT, where only several square meters of 
space are needed. However, when an appropriate space is available, the SPWT is a much 
cheaper alternative to the MTT, as the cost of a motorized treadmill can be prohibitive.  
 
Responsiveness of Walking Test 
Overall, the study cohort demonstrated evidence of clinical improvement between initial 
and final completion of self-reported measures, making the assessment of responsiveness 
of SPWT and MTT plausible. Improvement was reflected by change scores that reached 
published improvement thresholds for LSS treatments for SSQ symptoms and physical 
function subscales, and ODI [35,36]. Back pain, leg pain and ODI walking item scores 
also improved, but clinically important threshold values for improvements of these 
measures are not widely agreed upon for LSS. Furthermore, the proposed criteria for use 
of  global change in clinical status as a reference standard for assessment of external 
responsiveness was met, as global improvement was reported by a majority of 
participants, and improved clinical status was confirmed by concurrent changes in most 
measures of pain and function. 
 
Examination of responsiveness produced several important findings. MTT did not 
demonstrate adequate internal responsiveness for our group of participants undergoing a 
variety of treatment, as MTT time and distance did not significantly change between 
initial and final testing, and effect sizes as measured by MTT were insignificant. These 
findings are in contrast to the observations noted in several studies of lumbar spine 
surgery for LSS where improved treadmill walking time and/or distances were 
documented [18,19,43-45]. As internal responsiveness is dependent on the magnitude of 
change induced by treatment, it is possible that the changes in walking produced during 
this study were less substantial than those that result from cohort of patients treated with 
spine surgeries, though this would not be supported by results published by Malmivaara 
et al [10]. Addition, the ceiling effect may have limiting the ability of MTT to fully 
measure walking capacities in some participants, thus underestimating actual 
improvement in walking. This would be most true for subject that were only moderately 
limited by NC, and therefore more likely to reach the test’s ceiling. MTT may best be 
able to detect changes in walking status in the most disabled individuals who are more 
likely to consider surgery [46].  
 
Modest internal responsiveness was demonstrated for SPWT, as mean walking time, and 
distance did improve between initial and final testing. This occurred despite similar 
ceiling effects, and offers evidence that SPWT may be responsive for detecting change in 
walking abilities following treatments of NC.  
 
Results from evaluation of external responsiveness are the most noteworthy findings of 
this study, as changes in scores for neither MTT nor SPWT closely corresponded with 
other measures of change in clinical status. These results are surprising for this group of 
participants with NC, as it was our assumption that actual limitations in walking ability 
were the major concern for these patients, and this would be reflected in strong 
relationships between changes in walking abilities and other outcomes dimensions. 
However, at least for SPWT, where modest improvements were documented, these 
improvements in measured walking were not significantly different for participants rating 
themselves as improved or not improved. These findings suggest that on an individual 
level, there is a substantial divergence between objective and subjective outcome 
dimensions. These findings are similar to those noted for chronic low back pain 
treatments, where improvements in objective measurements of back flexibility, strength 
and lifting ability show weak (if any) relationships with changes in pain and function 
[47,48]. This does not suggest that changes in objective measures of function are 
irrelevant to the outcome of patients with spinal disorders, but instead that the magnitude 
of changes in objective measures has limited predictive value concerning subjective 
changes in clinical status. 
 
 
CONCLUSION 
Both MTT and SPWT can assessment the walking limitations that result from NC. In 
terms of outcomes measures for clinical trials, SPWT demonstrates greater internal 
responsiveness than MTT for the modest change in clinical status noted in this study.  
MTT demonstrated slightly better external responsiveness than SPWT, but external 
responsiveness was generally insufficient for both test, as changes in objective walking 
test show little concordance with patients’ perceptions of change in clinical status. We 
conclude that objective measures of walking ability such as SPWT and MTT can be used 
as a distinct outcome measure following treatment of NC, but are not superior to self-
reported walking abilities, not are they a substitute for disease specific measures of pain 
and function.
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Table 1. Comparisons of walking results from self-paced walking test (SPWT) and 
motorized treadmill test (MTT) using paired-sample t-test. (N = 45 participants that 
completed both tests) 
 
 MTT SPWT Difference 95% CI Sig 
      
    Time (minutes) 14.2 13.7 0.4 -1.7 – 2.6 .68 
    Distance (m) 711 872 161 31 – 290 .02 
    Speed (km/h) 2.6 3.7 1.1 0.7 – 1.4 .01 
95 % CI – 95 percent confidence interval for difference; m – meters; km/h – kilometers 
per hour 
Table 2. Pearson correlations between walking abilities as measured with self-paced 
walking test (SPWT) and motorized treadmill test (MTT) and self-reported walking 
measures. (Significance ≤ .01 for all correlations.) 
 
 MTT  SPWT  
Self-Report Measures Time  Distance Time Distance 
   Estimated Time .73 .70 .56 .63 
   Estimated Distance .66 .72 .58 .65 
   ODI Walking  -.63 -.54 -.47 -.49 
   SSQ Phys Function -.63 -.45 -.58 -.55 
SSQ Phys Function – Spinal Stenosis Questionnaire Physical Function Subscale; ODI 
walking – Oswestry Disability Index walking item 
 
Table 3. Comparisons by paired sample t-test of initial to final results for self-report 
measures. (N=39) 
 
Self-Report Measure Initial  Final  Diff 95% CI Sig. 
  Walking Time (min) 15.9  27.0  11.1 4.2 – 18.1 .003 
  Walking Distance (m) 628  1837  1209 240 – 2179 .016 
  Back Pain 6.1  3.9  2.2 1.2 – 3.1 .001 
  Leg Pain 5.4  3.4  2.0 1.2 – 3.1 .001 
  SSQ symptoms 3.0  2.5  0.5 0.3 – 0.7 .001 
  SSQ Phy Func 2.4  1.9  0.6 0.4 – 0.8 .001 
  ODI Walking 3.6  2.3  1.3 0.8 – 1.7 .001 
  ODI Total 35  23  11.7 6.1 – 17.2 .001 
Diff – mean difference; 95% CI – 95% confidence interval for mean differences; min – 
minutes; m – meters; km/h – kilometers per hour; SSQ symptoms – Spinal Stenosis 
Questionnaire Symptoms Subscale; SSQ Phy Func – Spinal Stenosis Questionnaire 
Physical Function Subscale; ODI Walking – Oswestry Disability Index Walking Item; 
ODI Total – Oswestry Disability Index Total Score 
  
Table 4. Internal responsiveness analyses for motorized treadmill test (MMT) and self-
paced walking test (SPWT) using paired sample t-test and effect size (ES). 
 
 Initial (SD) Final (SD) Mean Diff 95% CI ES 
MTT (N=32)      
  Time (min) 14.3  16.2  1.9  -.93 – 4.7 .17 
  Distance (m) 760  834  74  -90 - 238 .09 
  Speed (km/h) 2.71  2.83  0.15  -0.2 – 0.1 .11 
      
SPWT (N=39)      
  Time (min) 12.7  18.1  6.1  2.9 – 9.2* .60 
  Distance (m) 794  1181  387  199 – 575* .51 
  Speed (km/h) 3.48  3.56  0.08  -0.3 - 0.2 .07 
      
* t-test significance <.01; min – minutes; m – meters; km/h – kilometers per hour 
Table 5. Pearson correlations between the changes in scores of self-reported measures 
with changes in scores for motorized treadmill test (MTT) and self-paced walking test 
(SPWT). 
 
 MTT  SPWT  
Self-Report Time Distance Time Distance 
       
Est. Walking Time  .48** .50** .07 .09 
Est. Walk Distance .37* .62** .08 .11 
SSQ Phys Funct .35 .41* .25 .36* 
ODI Walking  .48** .35 .17 .23 
     
Significance *.05, **.01; Spinal Stenosis Questionnaire Symptoms Subscale; SSQ Phy 
Funct – Spinal Stenosis Questionnaire Physical Function Subscale; ODI walking – 
Oswestry Disability Index walking item score 
 
Figure 1. Receiver operating characteristics (ROC) curves for correct classification of 
improved global clinical status by changes in walking time and distance as measured by 
self-paced walking test (SPWT). 
 
 
 
 
  
Figure 2. Receiver operating characteristics curves (ROC) for correct classification of 
improved global clinical status by changes in walking time and distance as measured by 
motorized treadmill test (MTT). 
 
 
